Form 4: Eli Lilly EVP Sells Shares Under 10b5-1 Plan

Eli Lilly & Co. Executive Vice President Ilya Yuffa sold 1,250 shares of common stock for $627.01 per share on August 11, 2025, as part of a pre-arranged trading plan.

Summary

• Ilya Yuffa, Executive Vice President and President of LLY USA & Global Capabilities at Eli Lilly & Co., reported a transaction involving the company's common stock.
• On August 11, 2025, Mr. Yuffa disposed of 1,250 shares of Eli Lilly common stock.
• The shares were sold at a price of $627.01 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Yuffa on February 12, 2025.
• Following this transaction, Mr. Yuffa directly beneficially owns 26,259.971 shares of Eli Lilly common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of an insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage personal finances and diversify holdings without implying a specific sentiment about the company's future performance.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This is a routine insider transaction for a pharmaceutical company executive, common for managing personal finances and diversifying holdings. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally not indicative of company-specific performance or broader industry trends.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, pre-scheduled insider transaction and does not reflect new information about the company's operational or financial health.

Key Dates

Keywords

Eli Lilly, LLY, Ilya Yuffa, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Pharmaceuticals